CareMax Beheer

Beheer criteriumcontroles 2/4

De CEO CareMax is Carlos de Solo, benoemd in May2011, heeft een ambtstermijn van 13.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.39M, bestaande uit 19.2% salaris en 80.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.65% van de aandelen van het bedrijf, ter waarde $ 90.82K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 2.8 jaar.

Belangrijke informatie

Carlos de Solo

Algemeen directeur

US$3.4m

Totale compensatie

Percentage CEO-salaris	19.2%
Dienstverband CEO	13.5yrs
Eigendom CEO	5.6%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Aug 14

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Jun 20

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

May 13

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Mar 11

CareMax: Numbers Are Strong, Compelling Value On Offer

Sep 16

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

Aug 09

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

Jul 02

Analyse CEO-vergoeding

Hoe is Carlos de Solo's beloning veranderd ten opzichte van CareMax's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$783m
Mar 31 2024	n/a	n/a	-US$645m
Dec 31 2023	US$3m	US$650k	-US$683m
Sep 30 2023	n/a	n/a	-US$207m
Jun 30 2023	n/a	n/a	-US$126m
Mar 31 2023	n/a	n/a	-US$103m
Dec 31 2022	US$3m	US$650k	-US$38m
Sep 30 2022	n/a	n/a	-US$52m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$2m	US$419k	-US$7m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	US$12m
Mar 31 2021	n/a	n/a	US$6m
Dec 31 2020	US$3m	US$112k	US$8m
Sep 30 2020	n/a	n/a	US$7m
Dec 31 2019	US$3m	US$48k	US$6m

Compensatie versus markt: De totale vergoeding ($USD 3.39M ) Carlos } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 642.87K ).

Compensatie versus inkomsten: De vergoeding van Carlos is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Carlos de Solo (45 yo)

13.5yrs

Tenure

US$3,386,890

Compensatie

Mr. Carlos A. de Solo is a Co-Founder of CareMax Medical Group, L.L.C., and serves as President, Chief Executive Officer and Director since May 2011. Mr. de Solo has experience in the healthcare industry....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Carlos de Solo	Co-Founder	13.5yrs	US$3.39m	5.65% $ 90.8k
Kevin Wirges	Executive VP	3.4yrs	US$1.35m	0.14% $ 2.3k
Alberto de Solo	Executive VP & COO	13.5yrs	US$1.82m	2.55% $ 41.1k
Erick Fernandez	Chief Accounting Officer	2.8yrs	geen gegevens	geen gegevens
Mark Llorente	Chief Administrative Officer & Head of MSO Operations	1.7yrs	geen gegevens	geen gegevens
Roger Ou	SVP of Finance & Investor Relations	no data	geen gegevens	geen gegevens
Meredith Longsworth	Senior VP	2.6yrs	geen gegevens	geen gegevens
Teresa McMeans	Chief Compliance Officer	2.6yrs	geen gegevens	geen gegevens
Niberto Moreno	Chief Medical Officer & President of Caremax MSO	no data	geen gegevens	geen gegevens
Nicole Cable	Chief Experience Officer	2.6yrs	geen gegevens	geen gegevens
Michael Jarjour	Chief Digital Officer	1.8yrs	geen gegevens	geen gegevens
Paul Rundell	Chief Restructuring Officer	less than a year	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CMAX.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Carlos de Solo	Co-Founder	13.5yrs	US$3.39m	5.65% $ 90.8k
Richard Barasch	Advisor to the Board	2.8yrs	US$565.56k	geen gegevens
Edward Borkowski	Independent Director	less than a year	geen gegevens	geen gegevens
Ralph de la Torre	Director	2yrs	US$205.00k	15.79% $ 254.0k
Kevin Berg	Independent Director	2yrs	US$216.35k	0.011% $ 170.3
Bryan Cho	Independent Director	3.3yrs	US$235.00k	0.47% $ 7.6k
Jose Rodriguez	Independent Chairman	3.4yrs	US$322.50k	0.036% $ 581.3
Vincent Omachonu	Independent Director	3.4yrs	US$205.00k	0.026% $ 417.3
Ryan O'Quinn	Independent Director	2yrs	US$225.00k	0.011% $ 170.3

2.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CMAX.Q wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

CareMax Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new directors

High number of new directors

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

CareMax, Inc. Appoints Ralph De La Torre as Director

High number of new and inexperienced directors

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

Recent updates

CareMax, Inc.(OTCPK:CMAX.Q) dropped from NASDAQ Composite Index

CareMax, Inc.(NasdaqGS:CMAX) dropped from S&P TMI Index

Interim DIP Financing Approved for CareMax, Inc.

Interim DIP Financing Approved for CareMax, Inc.

CareMax, Inc. Filed for Bankruptcy

CareMax, Inc. announced delayed 10-Q filing

Consensus EPS estimates fall by 125%, revenue upgraded

High number of new directors

CareMax Receives Non-Compliance Notice from Nasdaq Regarding Minimum MVPHS Requirement

Consensus EPS estimates upgraded to US$20.83 loss, revenue downgraded

US$2.60: That's What Analysts Think CareMax, Inc. (NASDAQ:CMAX) Is Worth After Its Latest Results

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$33.26 loss

New major risk - Financial position

High number of new directors

CareMax, Inc. announced delayed annual 10-K filing

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

CareMax Announces 1-for-30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

CareMax Receives Non-Compliance Notice From Nasdaq

New major risk - Share price stability

New minor risk - Market cap size

Consensus EPS estimates fall by 64%

Price target increased by 9.1% to US$6.00

Consensus EPS estimates fall by 105%

New minor risk - Profitability

Caremax, Inc. Reports Unaudited Goodwill Impairment for the Three Months Ended September 30, 2023

CareMax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

Consensus EPS estimates fall by 18%, revenue upgraded

Price target decreased by 11% to US$6.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Revenue Guidance for the Full Year of 2023

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Consensus EPS estimates upgraded to US$0.28 loss, revenue downgraded

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

Caremax, Inc. Reaffirms Full Year 2023 Guidance

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$0.42 loss

Consensus EPS estimates upgraded to US$0.49 loss, revenue downgraded

Consensus revenue estimates fall by 12%

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.50

CareMax, Inc. Appoints Ralph De La Torre as Director

Consensus forecasts updated

High number of new and inexperienced directors

CareMax, Inc. (NasdaqGS:CMAX) completed the acquisition of Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Earnings Guidance for the Full Year 2022

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

CareMax, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CareMax, Inc., Annual General Meeting, Nov 02, 2022

CareMax: Numbers Are Strong, Compelling Value On Offer

Price target decreased to US$11.10

Consensus estimates of losses per share improve by 14%

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. Revises Earnings Guidance for the Full Year 2022

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

CareMax, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$11.00

High number of new and inexperienced directors

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

CareMax, Inc. (NasdaqGS:CMAX) entered into an agreement to acquire Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC for approximately $135 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie